Ragkun Wart Remover

Description

The product is identified by SPL Code 34089-3 and is presented as a white to off-white, round, biconvex tablet, which is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, talc, hydroxypropyl methylcellulose, titanium dioxide, and iron oxides (red and yellow).

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Common warts are characterized by their rough, “cauliflower-like” appearance on the surface, while plantar warts are specifically located on the bottom of the foot, presenting with tenderness and an interruption of the footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely.

The medication is to be applied by gently squeezing the tube to dispense one drop at a time, ensuring that each wart is sufficiently covered. Following application, the treated area should be allowed to dry.

This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

There are no specific contraindications listed for this product. However, it is essential to keep the product out of reach of children to prevent accidental ingestion. In the event of swallowing, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted.

Warnings and Precautions

For external use only, this product is flammable and must be kept away from fire and flame. It is contraindicated for use on irritated skin or any area that is infected or reddened. Additionally, it should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Caution is advised for individuals with diabetes or poor blood circulation, as the product may exacerbate existing conditions.

In the event of accidental ingestion, immediate medical assistance should be sought. Healthcare professionals are advised to contact a Poison Control Center at 1-800-222-1222 without delay.

Patients are encouraged to discontinue use and consult their healthcare provider if any adverse reactions occur, although specific instructions for cessation were not provided in the available information.

Side Effects

Patients should be aware that the product is for external use only and is flammable; it should be kept away from fire and flame. The use of this product is contraindicated on irritated skin or any area that is infected or reddened. Additionally, it should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes.

Patients with diabetes or poor blood circulation should not use this product due to potential adverse effects associated with these conditions.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified in the available data. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Ragkun Wart Remover (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

There is no specific information regarding the use of Ragkun WART REMOVER (salicylic acid liquid) in geriatric patients. The prescribing information does not provide guidance on dosage adjustments, safety concerns, or special precautions for elderly patients. Therefore, healthcare providers should exercise caution and consider individual patient factors when prescribing this medication to geriatric patients, as the absence of specific data necessitates careful monitoring and assessment of treatment efficacy and safety in this population.

Pregnancy

The safety of salicylic acid during pregnancy has not been established. Salicylic acid is contraindicated in pregnancy due to potential risks to the fetus, which may include a risk of fetal harm if used during this period. Pregnant women should avoid using this product unless directed by a healthcare provider. It is essential for healthcare professionals to counsel women of childbearing potential regarding these risks and to consider alternative treatments when necessary.

Lactation

Nursing mothers should exercise caution when using this product due to the potential for excretion in breast milk. It is recommended that lactating mothers consult a healthcare provider before using this product while breastfeeding to assess any potential risks to the infant.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution when administering the medication. It is essential to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, immediate medical attention should be sought. Healthcare providers should implement supportive measures as necessary, which may include symptomatic treatment and monitoring of vital signs.

Due to the lack of detailed overdosage information, it is recommended that healthcare professionals refer to established clinical guidelines and protocols for managing overdose situations relevant to the specific medication in question. Additionally, contacting a poison control center may provide further guidance on appropriate management strategies.

Continued vigilance and patient assessment are crucial in mitigating potential risks associated with overdosage.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events have been documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. It is important to emphasize the potential risks associated with swallowing the medication. In the event of accidental ingestion, patients should be instructed to seek medical help immediately or contact a Poison Control Center at 1-800-222-1222 for guidance.

Storage and Handling

The product is supplied in a tube format. It should be stored at room temperature, ensuring that it is kept away from excessive heat, specifically temperatures exceeding 37°C (99°F). To maintain hygiene and product integrity, it is recommended to wipe the tip of the tube with a paper towel between uses.

Additional Clinical Information

The product is administered topically, with patients instructed to apply one drop at a time to adequately cover each wart. This application should be allowed to dry, and the procedure may be repeated once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks.

Clinicians should counsel patients to keep the product out of reach of children and to seek medical assistance or contact a Poison Control Center immediately if swallowed. It is for external use only and is flammable; therefore, it should be kept away from fire and flame. Patients should avoid using the product on irritated skin, infected or reddened areas, moles, birthmarks, warts with hair, genital warts, or warts on the face or mucous membranes. Additionally, caution is advised for individuals with diabetes or poor blood circulation. Patients are encouraged to wash the affected area, soak the wart in warm water for 5 minutes, dry the area thoroughly, and wipe the tip of the tube with a paper towel between uses.

Drug Information (PDF)

This file contains official product information for Ragkun Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)